Vivos Therapeutics

VVOS

Market cap $19.2M

LITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that it has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023, and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share.

Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vivos Therapeutics, Inc. (VVOS) Discusses Strategic Business Model Pivot and Transition in Sleep Apnea Treatment Approach Transcript

LITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), is pleased to announce the grand opening of its latest sleep testing and treatment center near Detroit in Auburn Hills, Michigan.

Vivos Therapeutics, Inc. ( VVOS ) Q3 2025 Earnings Call November 19, 2025 5:00 PM EST Company Participants Bradford Amman - CFO, Treasurer & Secretary R. Huntsman - Co-Founder, Chairman of the Board & CEO Conference Call Participants Lucas Ward - Ascendiant Capital Markets LLC, Research Division Robert Sassoon - Water Tower Research LLC Presentation Operator Good day, everyone, and welcome to the Vivos Third Quarter 2025 Conference Call.

Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today reported financial results and operating highlights for the three and nine months ended September 30, 2025.

LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it plans to release its third quarter 2025 financial results after market close today, Wednesday, November 19, 2025.

Vivos Therapeutics, Inc. ( VVOS ) Shareholder/Analyst Call November 4, 2025 12:00 PM EST Company Participants R. Huntsman - Co-Founder, Chairman of the Board & CEO Bradford Amman - CFO, Treasurer & Secretary Jennifer Hauser Conference Call Participants Donna M.

LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today released previously unpublished clinical data confirming that treatment with Vivos' FDA-cleared Daytime-Nighttime Appliance (DNA) can provide children with Attention-Deficit/Hyperactivity Disorder (ADHD) and OSA significant relief and improvement in their quality of life.

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed published data confirming that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating children suffering from OSA.